Form 4: Lyell Immunopharma COO Executes Tax-Related Stock Sale
Statement of Changes in Beneficial Ownership
Lyell Immunopharma Chief Operating Officer Stephen J. Hill sold 89 shares of common stock to satisfy tax withholding obligations.
Summary
- Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc. (LYEL), sold 89 shares of common stock.
- The transaction occurred on May 11, 2026, at a weighted average price of $18.92 per share.
- The sale was executed automatically to cover tax withholding obligations related to the settlement of vested restricted stock units.
- Following the transaction, the reporting person maintains beneficial ownership of 17,894 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a discretionary divestment.
Positives
- The sale was non-discretionary and specifically intended to satisfy tax obligations, indicating it was not a signal of negative sentiment regarding company performance.
Negatives
- Reduction in direct equity holdings by a key executive.
Risks
- None identified; this is a routine administrative transaction.
Future Outlook
Not applicable; this is a retrospective disclosure of an insider transaction.
Industry Context
StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice in the biotechnology sector for executives receiving equity-based compensation, and they generally do not reflect management's outlook on the company's clinical or commercial progress.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for executive compensation tax management.
- The use of Rule 10b5-1(c) or automatic sell-to-cover plans is consistent with industry norms for publicly traded biotech firms.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was small and non-discretionary.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/11/2026 | Date of the stock sale transaction. |
| 05/18/2026 | Date of acquisition of 188 shares under the Employee Stock Purchase Plan. |
| 06/15/2026 | Date of filing of the Form 4. |
Keywords
Lyell Immunopharma, LYEL, Insider Trading, Form 4, Biotech, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.